Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

  • Caribou Biosciences Inc CRBU announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). 
  • Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6 patients) was observed as the best response. 
  • Related: Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study.
  • At 6 months following the single dose of CB-010, 40% of patients remained in CR (2 of 5 patients) as of the May 13 data cutoff date. 
  • One patient suffered grade 3 immune effector cell-associated neurotoxicity syndrome that resolved in 39 hours. Still, none of the patients experienced graft-versus-host disease or grade 2 or greater cytokine release syndrome (CRS). Two patients had grade 1 CRS. 
  • Caribou has begun enrolling patients at the second dose level, 80 million CAR-T cells. Doubling the dose could drive longer-lasting responses.
  • "Our conviction is intact that the recent dataset positions CRBU to potentially differentiate vs. competitors in a meaningful and favorable way as data matures and the company explores larger patient numbers and higher dose(s)," SVB Securities wrote. 
  • HC Wainwright says that CB-010's response rate and the complete response rate are more competitive than those seen with the FDA-approved CAR-T agents. 
  • It notes that Gilead Sciences Inc's GILD Yescarta demonstrated a 74% ORR (54% CR) and 94% ORR (79% CR) in DLBCL and FL, respectively, and Novartis AG's NVS Kymriah demonstrated a 53% ORR (39% CR) and 87% ORR (68% CR) in DLBCL and FL, respectively.
  • Price Action: CRBU shares are down 25.70% at $5.16 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CareSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!